Does bevacizumab increase the risk of cardiac ischemia and arterial thromboembolic events in cancer patients?
Bevacizumab treatment in cancer patients is associated with a significantly increased risk of cardiac ischemic and arterial thromboembolic events.
Treatment with bevacizumab may significantly increase the risk of cardiac ischemic events in cancer patients.
Ranpura et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: